Next Generation Diagnosis
The industry is witnessing significant disruptions around new regulations (PAMA implementation, deployment of laboratory developed tests) and move towards decentralized testing (home & retail type settings). Laboratory managers, ACOs and corporate executives need actionable insights to mitigate these disruptions and discover new growth opportunities in Point of Care Testing, Molecular Diagnostics, Laboratory Automation, and Smart Genomics markets.
Frost & Sullivan’s Next Generation Diagnosis Research Program
Next Generation Diagnosis program provides a truly end-to-end perspective analysis of ‘white space’ opportunities across IVD and Genomics markets. It enables companies to stay ahead of the shift to Direct to Consumer testing, track investments in Biomarkers (companion diagnostics) and adapt new business models in Clinical Laboratory services and Lab Automation markets. The team offers expert coverage on a variety of issues including profitable growth opportunities and partnerships with start-ups to strengthen position in the emerging data-driven ecosystem.
Frost & Sullivan’s expertise in Next Generation Diagnosis research and consulting includes work in the following strategic and operational areas:
Molecular Diagnostics & Companion Diagnostics
High convergence of molecular diagnostics and big data analytics will enable predictive analytical capabilities for diagnostic platforms. Several in vitro diagnostic (IVD) companies are expanding their product portfolios to include liquid biopsy and companion diagnostics (CDx) in their long-term strategies. Our research coverage includes tissue diagnostics, liquid biopsy, digital pathology and pre-natal diagnostics and biomarkers for combination therapies.
Point Of Care Testing (POCT) & Smart Genomics
New business models such as expansion into retail clinics, mobile clinics, and patient self-testing platforms (apps) have opened up several new opportunities for POCT companies. Suppliers are pushed to innovate on product capabilities (accuracy) and connectivity (communication with EMR, LIS systems). Research labs have jump-started spending on cloud, NGS and big data analytics solutions. Our research coverage includes infectious disease diagnostics, cardiac biomarkers, in vitro fertilization (IVF) services, and direct to consumer testing.
Adoption of digital workflow management practices and automated solutions is a key growth driver for labs to improve their efficiency and reduce cost. Over the last 10 years, the industry has witnessed a large number of M&A activities, as large companies were looking to aggressively expand their product portfolio and customer base. Genomics solutions are expected to witness higher growth than proteomics. Our research coverage includes clinical lab services, aftermarket functional consumables, and future of smart labs.
Book a complimentary one-hour Growth Pipeline Dialog™ session with our Healthcare & Life Sciences experts.
Greg Caressi is responsible for Frost & Sullivan’s Healthcare and Life Sciences practice, which includes Digital Health, Life Sciences, Medical Imaging & Informatics, and Advanced Medical Technologies. He engages with industry leaders across the globe regarding their technology needs and gaps, and leverages insights from our research to identify growth opportunities and needed solution capabilities for healthcare stakeholders, including healthcare providers, payors, government agencies, medical technology vendors and individual consumers.
Reenita Das currently serves as Healthcare and Life Sciences’ Partner and Senior Vice President and is the first woman Partner at Frost & Sullivan, driving the global research vision and strategy for the firm as well as commercial opportunities within the healthcare practice. She has lived and worked in over 10 countries in the world, focusing on finding solutions to healthcare challenges and implementing growth change strategies. She recently got voted the top 100 women in Femtech and Healthtech. Reenita’s focus is on how healthcare will operate 20 years from today and she shares her vision at leading conferences and events.
She is also passionate about using digital solutions and creating gender-specific healthcare by her focus on “Femtech” and the growth opportunities from this new sector which includes advising companies on the right strategies and commercial business models to success.
Dinesh Sampath Rangaraj
With more than 24 years of industry experience, Nitin serves as Frost & Sullivan’s Global Practice Area Leader (HLS). In this role, he is dedicated to executing strategy consulting, forecasting analytics, commercial due diligence and clinical R&D projects for healthcare companies.
Nitin has a strong understanding of the dynamics in the healthcare industry and possesses domain knowledge in the life sciences space. He has advised several mid sized companies and start-ups in numerous commercial transactions and IPOs to optimize market positioning and valuation strategies.
He has led strategic initiatives with Medical Device & Life Science companies:
- Emerging markets go to market strategy , Innovative therapies portfolio analysis
- Sales, Marketing, Distribution planning
- Global Alliances, Public Private Partnerships, M&A.
- Co-innovation programs, research
Charlie leads Frost & Sullivan’s growth consulting practice in the Americas supporting clients across the healthcare technology and services ecosystem. His responsibilities include project management, business development, strategic planning and subject matter expertise, particularly in the medical devices market.
Siddharth (Sid) Shah leads the global medtech research program of the Healthcare & Life Sciences practice, and has over ten years of healthcare market research & consulting experience. In his prior life he has also conducted wet lab research in stem cells at the prestigious Johns Hopkins University. Beyond medical devices, Shah also tracks innovations in radiology artificial intelligence, diabetes, and connected devices. He holds a Master of Science in Biotechnology from the Johns Hopkins University.
Daniel leads the growth consulting practice for Healthcare & Life Sciences in the Middle East & Africa. This practice covers Healthcare Delivery & Operations, Medical Imaging & Informatics, Pharmaceuticals & Life Sciences, and Digital Health.
Daniel is a seasoned healthcare professional with more than 15 years’ experience in the healthcare industry and has extensive experience supporting clients to achieve their strategic growth objectives through Optimization, Efficiency, Quality and Cost Initiatives; Market Analysis, Customer VOC/Perception studies, Due Diligence, and Service Expansion; Healthcare Data and Analytics; Change, Program and Project Management; and, Leadership Development.
Imran has over 20 years of experience in market research and consulting, covering a range of information and communication technologies across multiple industry verticals and enterprise and consumer segments.
The Clinical Diagnostics & Research Tools team utilizes a proven methodology that leverages Frost & Sullivan’s proprietary forecast models, access to high-quality internal and external published content, and information gained from primary research interviews. The team provides the content that goes well beyond the basic news that everyone can access.